Business Description
AN2 Therapeutics is a drug development company based in Menlo Park, California, that uses its boron chemistry platform to create new treatments for infectious diseases and cancer. Its lead drug, epetraborole, is currently in late-stage clinical trials as a daily oral pill for patients with non-tuberculous mycobacterial lung disease and is also being explored as a treatment for acute melioidosis. The company has additional programs in early development, including a treatment for chronic Chagas disease, and holds licensing partnerships with Anacor Pharmaceuticals, Brii Biosciences, and GSK to support the development and commercialization of its compounds across multiple markets.
